R&D channel feed

FDA spurns Min­er­va’s schiz­o­phre­nia drug in RTF, send­ing share price in­to tail­spin

3 years ago
FDA+

Up­dat­ed: Mile­stone Phar­ma claims PhI­II re­demp­tion for its once-failed heart drug, putting it on a path to the FDA

3 years ago

In­otrem’s sep­tic shock drug pass­es mid-stage test — but on­ly for some pa­tients

3 years ago

With da­ta from nine-pa­tient study, Vec­tivBio rais­es $125M ahead of lead pro­gram's big read­out

3 years ago
Financing

A Col­orado biotech ends clin­i­cal work to fo­cus on mar­ket­ing AD­HD drug, con­sumer health prod­ucts

3 years ago

The buck stops ear: Hear­ing loss biotech to look for 's­trate­gic op­tion­s' as da­ta analy­ses prove fruit­less

3 years ago

Rel­ma­da re­ports a PhI­II fail, blam­ing 'para­dox­i­cal' place­bo ef­fect — shares wiped

3 years ago

On Pfiz­er's heels, GSK boasts 'tru­ly ex­cep­tion­al' PhI­II da­ta for RSV vac­cine — mak­ing a bee­line to FDA

3 years ago
Pharma

Up­dat­ed: Bridge­Bio's $2.4B part­ner­ship takes a sud­den hit as Helsinn plans to with­draw NDA on FGFR2 drug

3 years ago
Deals
Pharma

Look­ing for an ad­van­tage in the crowd­ed SMA space, Roche’s Genen­tech re­leas­es fresh Evrys­di da­ta

3 years ago
Pharma

Mer­ck pays Mod­er­na $250M to con­tin­ue Keytru­da, can­cer vac­cine com­bo stud­ies

3 years ago
Deals

De­spite $109M in­flux in Au­gust, Green­Light Bio­sciences brings out the axe to chop a quar­ter of its staff

3 years ago
People
Manufacturing

With help from Lu­l­ule­mon founder’s ven­ture phil­an­thropy, Vi­ta adds sec­ond mus­cu­lar dy­s­tro­phy in­di­ca­tion to line­up

3 years ago
Financing

Evofem's ap­proved birth con­trol gel flops PhI­II for STI pre­ven­tion, ear­ly 2023 fil­ing plans ditched

3 years ago

At­las-backed biotech fo­cused on Hunt­ing­ton's dis­ease shuts down less than three years af­ter launch

3 years ago

Sang­amo gives an­oth­er up­date on ear­ly-stage Fab­ry pro­gram, en­ters tri­al ex­pan­sion phase

3 years ago
Cell/Gene Tx

More ear­ly da­ta ma­nip­u­la­tion is­sues tied to No­var­tis block­buster as Na­ture re­tracts pa­per

3 years ago
Cell/Gene Tx

Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

3 years ago

No speedy nasal roll­out for Ox­ford/As­traZeneca’s Covid-19 jab af­ter PhI flop

3 years ago
Pharma
Coronavirus

Im­mat­ics spot­lights more ear­ly da­ta for TCR cell ther­a­py in sol­id tu­mors — now let's see if it lasts

3 years ago
Cell/Gene Tx

J&J's Janssen un­veils PhII ul­cer­a­tive col­i­tis da­ta for Trem­fya com­bo, look­ing to ex­pand the drug's foot­print

3 years ago

A liv­er dis­ease up­start with some glob­al con­nec­tions and a new R&D strat­e­gy reaps a $30M launch round

3 years ago
Financing

The crown jew­el in Mer­ck’s $11.5B Ac­celeron buy­out just cleared a piv­otal PhI­II

3 years ago

Amid al­ready plung­ing use of Mer­ck’s Covid-19 an­tivi­ral Lagevrio, preprint gives look in­to re­al world per­for­mance

3 years ago
Coronavirus
First page Previous page 115116117118119120121 Next page Last page
A service from the Financial Times